Posts Tagged: CTC


CTCs as prognostic markers for metastatic breast cancer

Circulating tumor cells (CTCs) are tumor cells circulating freely in the peripheral blood of patients. The characterization of CTCs is considered as a real-time “liquid biopsy” that provides an ongoing picture of a patient’s cancer status, offering valuable insight into personalized anticancer therapy. CTCs are very rare and highly heterogeneous, possessing tumor-specific antigenic and genetic characteristics. One… Read article →


Circulating tumor cell assays and bladder cancer care

In the United States, bladder cancer is surprisingly common, accounting for 4.5% of all new cancer cases in 2015 (1). Worldwide, approximately 365,000 cases are reported every year (2). Clinically, bladder cancer is classified as non-muscle-invasive (70% of new cases), muscle-invasive (20% of new cases), or metastatic (5%) (3). For non-muscle-invasive disease, first-line treatment is resection of… Read article →


This year’s top liquid biopsy conferences around the world

One of the most-discussed technologies of 2015 was liquid biopsy-based translational research and its future importance in precision medicine. In 2016, even more dedicated conferences will focus on liquid biopsy, with leaders in industry and academia discussing the potential of this essential tool of personalized healthcare going forward. As I have been following this topic very closely over the last year, I… Read article →


The Future’s So Bright: Liquid Biopsy in 2016

Basic scientists, clinicians and market analysts are all optimistic about the prospects for liquid biopsy in 2016. Several reports have determined that liquid biopsy is a growing market segment for cancer diagnosis and management (1–2), expected to reach $20 billion in the next five years (1). Biotech startups and major companies alike have jumped in… Read article →